Clinical Pharmacist - Educator
About the job
- Current registration as a Pharmacist with the College of Pharmacists of British Columbia.
- Successful completion of an approved Hospital Pharmacy Residency Program supplemented with three years of recent related hospital pharmacy experience, including one year of pharmacy leadership and staff education experience, or an equivalent combination of education, training and experience.
- Comprehensive knowledge of organization policies, procedures, and standards of care.
- Comprehensive knowledge of pharmacy theory and practice within a client- and family-centred model of care.
- Broad knowledge of established provincial standards of practice and guidelines for clinical practitioners.
- Broad knowledge of adult education theory.
- Broad knowledge of other health care disciplines and their role in client care.
- Ability to develop and construct effective and dynamic education modules.
- Ability to lead, coach, facilitate and teach, including oversight of student and resident projects.
- Ability to promote a creative learning environment.
- Ability to promote a culture of enquiry and evidence-based practice.
- Ability to communicate verbally and in writing.
- Ability to plan, organize and prioritize work.
- Ability to operate related equipment, including applicable software applications.
- Physical ability to perform the duties of the position.
- Provide individualized pharmacotherapy and counsel patients about their medication therapy.
- Collaborate with physicians and other health care providers to develop, implement and monitor therapeutic plans.
- Assist in developing drug therapy guidelines for individual disease conditions.
- Prepare and submit case studies and articles sharing new knowledge for publication in professional journals.
- Act as a department resource person within the assigned area.
- Participate in medication use evaluations, quality improvement initiatives and clinical drug trials.
- Provide mentorship and supervision to pharmacy students, residents and new staff.
- Ensure prescriptions are validated and dispensed accurately, resolve medication safety concerns and discrepancies with the health care team, and document professional practice activities.
- Collaborate with Pharmacy Coordinators to identify pharmacy staff learning needs and implement and evaluate educational strategies and programs through teaching, coaching, orienting and training pharmacists.
- Develop, implement and evaluate educational materials for ongoing rollout of new policies, procedures, skills and competencies, and work with Pharmacy Coordinators to implement changes as required.
- Identify education priorities that meet staff learning needs, complete learning needs assessments of individuals or groups, determine appropriate training requirements and learning objectives, and provide education and training on standards, clinical guidelines, professional practice resources, practice-based research procedures and education materials.
- Provide leadership, direction and guidance on pharmacy education, research and related special project initiatives through training, orientation, planning, implementation and evaluation of continuing professional education in collaboration with Pharmacy Coordinators.
- Arrange, plan and conduct formal training sessions in response to identified employee learning, training or clinical needs; provide resources and materials to clinical areas and external facilities as required; and collaborate with Pharmacy Coordinators on education strategies and innovations based on organizational goals and evidence-based pharmacy practice.
- Maintain records of staff orientation and instruction.
- Coordinate new staff orientation for pharmacists and other designated staff with Pharmacy Coordinators, ensuring familiarity with pharmacy practice standards, clinical guidelines, professional practice resources, education materials and modules; communicate and consult with Coordinators to share information and coordinate educational sessions.
- Review and evaluate literature, consult with other professionals, attend relevant educational programs, maintain knowledge of current developments, contribute to improvement of pharmacy services and promote continuous learning among staff.
- Participate in and lead quality improvement initiatives and related audits, and promote practices that ensure safe client, patient and resident care and improve service.
- Participate on clinical committees and working groups as required, providing input and recommendations to the site pharmacy leadership team.
- Provide clinical pharmacy and drug distribution services in assigned areas to maintain practice skills and proficiency.
- Perform other related duties as assigned.
About the company
Fraser Health is a health authority in British Columbia that provides a wide range of medical services to about 1.8 million people. It operates 12 hospitals, including major trauma centres, plus an outpatient care and surgery centre, and offers residential care, home health, public health, and mental health services. The organization employs over 40,000 staff, medical professionals, and volunteers who run clinics, care centres, and community programs. Its goal is to deliver accessible, high-quality care across the network while creating good workplaces for its employees and volunteers.
Company Size
10,001+
Company Stage
Grant
Total Funding
$20K
Headquarters
Surrey, Canada
Founded
2001
Get referred to Fraser Health
See people who can refer or advise you
Simplify's Take
What believers are saying
- The $18 million Mission Memorial ED expansion started construction in February 2026.
- The Cloverdale UPCC opened January 28, 2026, with capacity for 64,000 annual visits.
- Fraser Health won $1.3 million in March 2026 to expand Indigenous elder home care in Chilliwack.
What critics are saying
- Mission Memorial ED faced repeated overnight shutdowns in May, June, and August 2026.
- Physician staffing gaps still force service interruptions, signaling fragile emergency coverage across the network.
- The Cloverdale hospital slipped from 2027 to 2030, weakening growth and credibility.
What makes Fraser Health unique
- Fraser Health runs 12 hospitals and serves 1.8 million people across British Columbia.
- Its Mission ED expansion adds 35% more space and reaches 41 care spaces by spring 2027.
- Deloitte-backed AI scheduling models forecast patient surges and staffing demand across Fraser Health.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Paid Vacation
Growth & Insights and Company News
6 month growth
↑ 11%1 year growth
↑ 11%2 year growth
↑ 11%Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II cardiac surgery-associated AKI trial. Rhea-AI Impact Rhea-AI Sentiment Rhea-AI summary. Arch Biopartners (OTCQB: ACHFF) announced a Clinical Trial Agreement with Fraser Health Authority to prepare Royal Columbian Hospital for recruitment in its Phase II trial of LSALT peptide for prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). Royal Columbian Hospital is now the ninth global site activated and the fourth Canadian recruiting site, after Toronto General Hospital, St. Michael's Hospital, and University of Calgary. Positive. * Royal Columbian Hospital received final Research Ethics Board and operational approvals * Royal Columbian Hospital became the 9th global site activated in the Phase II CS-AKI trial * 4 Canadian sites are actively recruiting patients (Toronto General, St. Michael's, Calgary, RCH) Negative. 03/24/2026 - 09:13 AM TORONTO, March 24, 2026 (GLOBE NEWSWIRE) - Arch Biopartners Inc. ("Arch" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the Fraser Health Authority has entered into a Clinical Trial Agreement ("CTA") with Arch to enable the Royal Columbian Hospital (RCH) to begin preparing for the recruitment phase in Arch's ongoing Phase II trial evaluating LSALT peptide for the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). With the Clinical Trial Application (CTA) completed, RCH has now received final Research Ethics Board and operational approvals, including the final letter of authorization from Fraser Health. RCH will be the ninth site activated globally in the study and will be the fourth site to recruit patients in Canada. Toronto General Hospital, part of University Health Network, St. Michael's Hospital, part of Unity Health Toronto, and the University of Calgary, Cumming School of Medicine, continue to actively enroll new patients into the trial. The Company is currently progressing feasibility and start-up discussions with additional leading cardiac surgery centres in Canada and the United States. About Arch Biopartners Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD). The Company is advancing an integrated program that includes new treatments targeting inflammation- and toxin-related kidney injury. Arch's development pipeline includes: * LSALT peptide: in a Phase II trial targeting cardiac surgery-associated AKI. * Cilastatin: a repurposed drug in a Phase II trial targeting toxin-induced AKI. * CKD Platform: next-generation therapeutics targeting chronic kidney disease. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting more than 800 million people worldwide[1]. Both lead programs are currently enrolling patients at Canadian clinical sites, with additional North American sites in development. For more details about the Company's science and ongoing clinical trials, please visit: www.archbiopartners.com/our-science Follow Arch on LinkedIn, Bluesky, and X (formerly Twitter) for scientific insights and industry news. The Company has 66,933,289 common shares outstanding. | Aaron Benson Director of Communications Arch Biopartners, Inc. 647-428-7031 | / | | / | / | Send a message or subscribe for trial updates and company news at www.archbiopartners.com/contact-us Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of the Company's future performance, liquidity, and capital resources, as well as the ongoing development of its drug candidates targeting chronic kidney disease and the dipeptidase-1 (DPEP-1) pathway, including the outcome of its clinical trials relating to LSALT peptide (Metablok) or cilastatin, the successful commercialization and marketing of its drug candidates, whether the Company will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe, and other countries, its ability to raise capital to fund its business plans, the efficacy of its drug candidates compared to the drug candidates developed by competitors, its ability to retain and attract key management personnel, and the breadth of, and its ability to protect, its intellectual property portfolio. These statements are based on management's current expectations and beliefs, including certain factors and assumptions, as described in the Company's most recent annual audited financial statements and related management discussion and analysis under the heading "Business Risks and Uncertainties". As a result of these risks and uncertainties, or other unknown risks and uncertainties, the actual results may differ materially from those contained in any forward-looking statements. The words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect", and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company undertakes no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including the Company's most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval ("SEDAR") website at www.sedarplus.ca. References: * Mark, Patrick B et al. Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023. The Lancet, 2025;406(10518), 2461 - 2482. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01853-7/fulltext The scientific and medical content of this release has been reviewed and approved by the Company's Chief Science Officer. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Faq. What does the Clinical Trial Agreement with Fraser Health mean for Arch Biopartners (ACHFF)? It enables Royal Columbian Hospital to prepare for patient recruitment in the Phase II CS-AKI trial. According to the company, RCH now has final Research Ethics Board and operational approvals plus a letter of authorization from Fraser Health, supporting site activation. How many sites are active in Arch Biopartners' (ACHFF) Phase II LSALT CS-AKI trial after Royal Columbian Hospital activation? Royal Columbian Hospital is the ninth site activated globally in the study. According to the company, RCH is also the fourth site in Canada to reach activation and prepare for recruitment. Which Canadian hospitals are currently recruiting for Arch Biopartners' (ACHFF) Phase II CS-AKI trial? Toronto General Hospital, St. Michael's Hospital, University of Calgary, and now Royal Columbian Hospital are recruiting. According to the company, those four Canadian centres are actively enrolling new patients into the trial. What approvals did Royal Columbian Hospital receive to start recruitment for the ACHFF Phase II trial? RCH received final Research Ethics Board and operational approvals plus a letter of authorization from Fraser Health. According to the company, these approvals complete site readiness for recruitment and study start-up activities. Will Arch Biopartners (ACHFF) add more sites in Canada and the US for the Phase II CS-AKI trial? The company is progressing feasibility and start-up discussions with additional cardiac surgery centres in Canada and the United States. According to the company, those discussions aim to expand site activation beyond the current nine global sites.
$1.3M funding will help more Indigenous elders in Chilliwack with at-home care. Published 8:45 am Saturday, March 14, 2026 An at-home program that offers care to Indigenous elders in the Fraser Valley will be expanding, with the main focus on Chilliwack, thanks to $1.3 million in new funding. The Indigenous Caregiver Support Model (ICSM) is a home-based program that supports elders with "complex needs to age safely at home and in their community," according to a Fraser Health press release. It is one of five programs in B.C. benefitting from a total of $6.3 million in funding from Health Research BC over the next three years. The funding will advance research to help B.C. seniors age comfortably in their own home. The ICSM program was launched in 2023 as a pilot project and has supported 33 elders and their caregivers in the Eastern Fraser Valley, including Chilliwack. Its aim is to reduce caregiver strain and improve elder wellbeing by providing culturally safe, coordinated in-home support, training, and financial assistance for Indigenous families caring for elders. It is co-designed by Fraser Health Indigenous Health, Stó:lō Service Agency, First Nations Health Authority, and Métis Nation British Columbia. "This model is an example of what is possible when care is built on relationships, trust and community," said Amanda LaBoucane, interim vice president, Indigenous Health and Cultural Safety. "Many elders and caregivers in the Chilliwack area have experienced firsthand the impacts of residential schools and the child welfare system. By strengthening caregiver capacity and confidence while bridging into integrated clinical care teams run by and for Indigenous people, we see improved health and wellness and stronger relationships within and between communities." The program is currently operating in the Fraser Valley, including Chilliwack, but the expansion will focus on urban Chilliwack as that is an identified need, said Carrie Stefanson with Fraser Health. Caregivers receive skills training and an honorarium to help reduce the economic strain of caregiving, while elders receive regular home visits from Indigenous-led clinical teams who provide culturally safe, relationship-based care, rooted in trust, kindness and respect, according to a Fraser Health.
Fraser Health has partnered with Deloitte Canada to develop and launch scheduling tools that leverage artificial intelligence (AI) and machine-learning solutions to accurately forecast the waves in demand Fraserhealth see in the health system.
For people not already connected to services, Fraser Health will work in partnership with Coast Mental Health to provide on-site clinical supports, including services from a psychiatric nurse, community nurse, licensed practical nurse, social worker and traditional wellness practitioners.
Through a procurement process, Fraser Health has selected Ellis-Don Design Build to design and build the new facility through a design-build agreement.